Opko Health Inc. (NYSE:OPK)‘s stock had its “hold” rating reiterated by equities researchers at Oppenheimer Holdings Inc. in a research note issued to investors on Monday.

A number of other research firms also recently weighed in on OPK. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Jefferies Group reissued a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. Standpoint Research increased their target price on shares of Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, June 21st. Deutsche Bank AG reduced their target price on shares of Opko Health from $11.00 to $10.00 and set a “hold” rating for the company in a research report on Thursday, June 16th. Finally, JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the company a “buy” rating in a research report on Tuesday, August 9th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $13.20.

Analyst Recommendations for Opko Health (NYSE:OPK)

Shares of Opko Health (NYSE:OPK) traded down 3.5487% on Monday, reaching $9.5969. 1,591,803 shares of the company’s stock traded hands. The company’s 50-day moving average price is $10.06 and its 200 day moving average price is $10.09. The firm has a market cap of $5.28 billion and a P/E ratio of 40.1544. Opko Health has a one year low of $7.12 and a one year high of $11.85.

Opko Health (NYSE:OPK) last released its earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.05. The company had revenue of $357.10 million for the quarter, compared to the consensus estimate of $324.11 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The firm’s revenue was up 742.2% on a year-over-year basis. On average, equities analysts forecast that Opko Health will post ($0.05) EPS for the current fiscal year.

In other Opko Health news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 27th. The stock was bought at an average cost of $9.91 per share, with a total value of $99,100.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at $30,413,304.41. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A number of hedge funds have recently bought and sold shares of OPK. California State Teachers Retirement System boosted its stake in Opko Health by 6.1% in the second quarter. California State Teachers Retirement System now owns 682,157 shares of the company’s stock valued at $6,371,000 after buying an additional 39,160 shares in the last quarter. Teachers Advisors Inc. boosted its stake in Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock valued at $3,379,000 after buying an additional 11,403 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Opko Health by 3.7% in the second quarter. Bank of New York Mellon Corp now owns 1,343,344 shares of the company’s stock valued at $12,547,000 after buying an additional 47,942 shares in the last quarter. BlackRock Group LTD boosted its stake in Opko Health by 19.1% in the first quarter. BlackRock Group LTD now owns 251,817 shares of the company’s stock valued at $2,616,000 after buying an additional 40,321 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC boosted its stake in Opko Health by 1.2% in the second quarter. Jaffetilchin Investment Partners LLC now owns 450,450 shares of the company’s stock valued at $4,207,000 after buying an additional 5,182 shares in the last quarter.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.